Overview

A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC

Status:
Unknown status

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is is to assess the safety and tolerability of curcumin in combination with EGFR-TKIs in selected patients with advanced non-resectable mutant EGFR NSCLC.

Phase:

Phase 1

Details

Lead Sponsor:

Lady Davis Institute

Collaborator:

Jewish General Hospital

Treatments:

Curcumin
Erlotinib Hydrochloride
Gefitinib